Figure 5.

Synergy of host-targeting agents on HCV infection. (A) Combination of receptor-specific (anti-CD81, anti-SR-BI or anti-CLDN1) mAbs and protein kinase inhibitors (erlotinib or dasatinib) was performed as described in figure 1 and the CIs at IC₅₀, IC₇₅ and IC₉₀ are indicated in online supplementary table S2. Means±95% credible intervals from three independent experiments performed in triplicate are shown. (B) Combination of anti-CLDN1 mAb and dasatinib (left) or erlotinib (right). (C) Synergy was confirmed using the Prichard and Shipman method.²⁵ (D) Combination of alisporivir and entry inhibitors was performed as described in figure 1 and the CIs at IC₅₀, IC₇₅ and IC₉₀ are indicated in online supplementary table S2. Means±95% credible intervals from three independent experiments performed in triplicate are shown. (E) Combination of alisporivir with erlotinib (left) or anti-CLDN1 mAb (right). (F) Synergy was confirmed using the Prichard and Shipman method.²⁵